Loading clinical trials...
Loading clinical trials...
The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL) when used to treat ectasia.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Topcon Medical Systems, Inc.
NCT06659640 · Hereditary Hemorrhagic Telangiectasia
NCT07215416 · Ataxia Telangiectasia
NCT06306963 · Gastric Antral Vascular Ectasia, Cirrhosis, and more
NCT07414446 · Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale, and more
NCT06573723 · Rare Diseases, Amyloidosis, and more
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona
Woolfson Eye Institute
Atlanta, Georgia
Minnesota Eye Consultants, P.A.
Bloomington, Minnesota
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions